Together, these results identify Lys637 acetylation as a previously unknown regulatory modification that compromises STAT1 function by preventing proper homodimerization, thereby reducing its transcriptional activity and ultimately blunting tumor cell response to IFN-γ in cetuximab-resistant HNSCC. The gene discussed is STAT1; the disease is neoplasm.